NEW YORK CITY, NY / ACCESS Newswire / January 11, 2026 / WHY: New York, N.Y., January 11, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ:SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January […]

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15th 2026 at 1:15 PM PST / 4:15 PM EST. in

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In StubHub To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of StubHub pursuant and/or traceable to StubHub’s registration statement for the initial public offering held on or about September 17, 2025 and would

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Sprouts to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Sprouts between June 4, 2025 and October 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

As 2026 begins, many people are setting goals to live healthier, stay active, and take control of their well-being. For those who rely on supplemental oxygen, maintaining optimal respiratory health is a key part of achieving these resolutions. VARON is supporting these efforts with the launch of the VP-8 Lite Portable Oxygen Concentrator–a lightweight, reliable,

NEW YORK CITY, NY / ACCESS Newswire / January 11, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Firefly Aerospace Inc. ("Firefly" or the "Company") (NASDAQ:FLY) and certain officers.�� The class action, filed in the United States District Court for the Western District of Texas, and docketed under 25-cv-01812,

(NASDAQ:ZYME), Positive Phase 3 HERIZON-GEA-01 results for Ziihera(R) (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China Company well-positioned to execute new strategy compounding long-term

(NasdaqGM:ESPR), – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – -Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva's President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company's milestones achieved